| Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives E Nicolò, F Giugliano, L Ascione, P Tarantino, C Corti, SM Tolaney, ... Cancer Treatment Reviews 106, 102395, 2022 | 103 | 2022 |
| Antibody–drug conjugates for the treatment of breast cancer C Corti, F Giugliano, E Nicolò, L Ascione, G Curigliano Cancers 13 (12), 2898, 2021 | 62 | 2021 |
| Therapeutic cancer vaccines revamping: technology advancements and pitfalls G Antonarelli, C Corti, P Tarantino, L Ascione, J Cortes, P Romero, ... Annals of Oncology 32 (12), 1537-1551, 2021 | 57 | 2021 |
| Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls S Morganti, M Ivanova, E Ferraro, L Ascione, G Vivanet, G Bonizzi, ... Cancer Drug Resistance 5 (4), 971, 2022 | 17 | 2022 |
| Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development P Tarantino, G Antonarelli, L Ascione, G Curigliano Expert opinion on investigational drugs 31 (6), 499-513, 2022 | 14 | 2022 |
| Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience M Repetto, E Crimini, LB Bielo, E Guerini-Rocco, L Ascione, A Bonfanti, ... European Journal of Cancer 183, 79-89, 2023 | 13 | 2023 |
| Challenges and obstacles in applying therapeutical indications formulated in molecular tumor boards E Crimini, M Repetto, P Tarantino, L Ascione, G Antonarelli, EG Rocco, ... Cancers 14 (13), 3193, 2022 | 13 | 2022 |
| The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 M Repetto, E Crimini, L Ascione, L Boscolo Bielo, C Belli, G Curigliano Investigational new drugs 40 (5), 1133-1136, 2022 | 12 | 2022 |
| Predicting response to antibody drug conjugates: a focus on antigens’ targetability L Ascione, E Crimini, D Trapani, A Marra, C Criscitiello, G Curigliano The Oncologist 28 (11), 944-960, 2023 | 10 | 2023 |
| Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases P Trillo, J Sandoval, D Trapani, E Nicolò, P Zagami, F Giugliano, ... European Journal of Cancer 185, 119-130, 2023 | 8 | 2023 |
| PIK3CAMutations in breast cancer subtypes other than HR-positive/HER2-negative L Ascione, P Zagami, E Nicolò, E Crimini, G Curigliano, C Criscitiello Journal of Personalized Medicine 12 (11), 1793, 2022 | 5 | 2022 |
| Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population L Mazzarella, F Giugliano, E Nicolo, A Esposito, E Crimini, G Tini, J Uliano, ... The Oncologist 29 (2), e266-e274, 2024 | 4 | 2024 |
| Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates L Ascione, L Guidi, A Prakash, D Trapani, P LoRusso, E Lou, G Curigliano American Society of Clinical Oncology Educational Book 44 (3), e431766, 2024 | 4 | 2024 |
| Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers C Belli, L Boscolo Bielo, M Repetto, E Crimini, R Scalia, A Diana, ... The Oncologist, oyae125, 2024 | 2 | 2024 |
| Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection D Trapani, J Sandoval, PT Aliaga, L Ascione, PP Maria Berton Giachetti, ... Breast Cancer Research and Treatment: Innovative Concepts, 63-88, 2024 | 2 | 2024 |
| Circulating Tumor DNA and Risk of Venous Thromboembolism in Locally Advanced Rectal Cancer L Gervaso, CA Cella, D Ciardiello, C Valenza, L Guidi, L Boldrini, ... Blood 142, 4013, 2023 | 2 | 2023 |
| Evaluation of the geographical accessibility of genome-matched clinical trials on a national experience E Crimini, G Tini, P Tarantino, L Ascione, M Repetto, P Beria, A Ranghiero, ... The Oncologist 29 (2), 159-165, 2024 | 1 | 2024 |
| Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study S Morganti, A Marra, S Gandini, L Ascione, M Ivanova, K Venetis, ... European Journal of Cancer 195, 113397, 2023 | 1 | 2023 |
| Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives L Ascione, G Castellano, G Curigliano, P Zagami Current Opinion in Oncology 36 (6), 465-473, 2024 | | 2024 |
| Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer C Koukoutzeli, D Trapani, L Ascione, E Kotteas, A Marra, C Criscitiello, ... Clinical Medicine Insights: Oncology 18, 11795549241260418, 2024 | | 2024 |
